40822 Federal Register / Vol. 74, No. 155 / Thursday, August 13, 2009 / Notices 

is to determine eligibility for the 340B 

program. This information is received 

and verified according to 340B 

requirements and entered into the 340B 

database. Accurate records are critical to 

implementation of the 340B legislation 

especially to prevent diversion and 

duplicate discounts. To maintain 

accurate records, the OPA requests 

entities to submit modifications to any 

administrative information that they 

submitted when initially enrolling into 

the program. The burden requirement 

for these processes is minimal. 

Contract Pharmacy Self-Certification 

In order to ensure that drug 

manufacturers and drug wholesalers 

recognize contract pharmacy 

arrangements, covered entities that elect 

to utilize a contract pharmacy are 

required to submit to OPA a selfcertification form similar to the 

registration form that they have signed 

an agreement with the contract 

pharmacy. 

The Estimates of annualized burden 

are as follows: 

Reporting requirement Number of 

respondents 

Responses 

per 

respondent 

Total 

responses 

Hours per 

response 

Total burden 

hours 

DSH & Children’s Hospital Enrollment, Additions & Recertifications 

340B Program Registrations & Certifications for Disproportionate Share Hospitals ...................................... 70 1 70 .25 17 .5 

340B Program Registrations & Certifications for Children’s Hospitals ............................................................ 80 1 80 .25 20 

Certifications to Enroll DSH & Children’s Hospitals Outpatient facilities to 340B Program ................................ 180 1 180 .083 14 .94 

DSH & Children’s Hospitals’ Annual Recertification ........ 937 1 937 .5 468 .5 

Registration for Entities Other Than Hospitals & Recertifications 

340B Registration Form (Family Planning, STD, TB, 

and others) ................................................................... 170 1 170 .083 14 .11 

Family Planning Annual Recertification ........................... 85 47 3995 .083 331 .59 

STD & TB Annual Recertification .................................... 111 11 1221 .083 101 .34 

Other Entity Annual Recertification for entities other 

than DSHs, FP, STD or TB entities ............................. 400 10 4000 .083 332 

Submission of Administrative Changes for any entity ..... 460 1 460 .083 38 .18 

Contracted Pharmacy Services Registration & Recertifications 

Contracted Pharmacy Services Registration ................... 2000 1 2000 .083 166 

Total .......................................................................... * 4493 ........................ 13,313 .......................... 1504 .16 

* The total number of respondents may be overestimated since we are unable to avoid duplication of respondents who submit information to 

the OPA over the course of participation in the 340B Drug Pricing Program, via the initial registration process to any updates/modifications and 

enrolling contract pharmacies, if applicable, to the recertification process. 

Written comments and 

recommendations concerning the 

proposed information collection should 

be sent within 30 days of this notice to 

the desk officer for HRSA, either by email to OIRA_submission@omb.eop.gov 

or by fax to 202–395–6974. Please direct 

all correspondence to the ‘‘attention of 

the desk officer for HRSA.’’ 

Dated: August 5, 2009. 

Alexandra Huttinger, 

Director, Division of Policy Review and 

Coordination. 

[FR Doc. E9–19381 Filed 8–12–09; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Health 

Promotion and Disease Prevention 

Research Centers, Special Interest 

Project Competitive Supplements 

(SIPS) (U48 Panels N, O and P), RFA– 

DP09–101SUPP09, Initial Review 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting. 

Time and Dates: 

9 a.m.–5 p.m., August 5, 2009 (closed). 

9 a.m.–5 p.m., August 6, 2009 (closed). 

9 a.m.–5 p.m., August 7, 2009 (closed). 

Place: Westin Hotel, 3377 Peachtree Road, 

NE., Atlanta, GA, 30326, Telephone (678) 

500–3100. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in section 552b(c)(4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters To Be Discussed: The meeting will 

include the review, discussion, and 

evaluation of the application received in 

response to ‘‘Health Promotion and Disease 

Prevention Research Centers, Special Interest 

Project Competitive Supplements (SIPS) (U48 

Panels N, O and P), RFA–DP09–101SUPP09, 

initial review.’’ 

Contact Person for More Information: 

Brenda Colley-Gilbert, Ph.D., Director, 

Extramural Research Program Office, CCH, 

47770 Buford Highway, MS K–92, Atlanta, 

GA 30341, Telephone (770) 488–8390. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. E9–19293 Filed 8–12–09; 8:45 am] 

BILLING CODE 4163–18–P 


erowe on DSK5CLS3C1PROD with NOTICES